NCT03435952 Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT03432741 Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer Status TERMINATED Phase PHASE1
NCT03432676 Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer Status WITHDRAWN Phase PHASE2
NCT03430700 Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer Status COMPLETED Phase PHASE2
NCT03428802 Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03426891 Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma Status COMPLETED Phase PHASE1
NCT03425643 Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT03425565 A Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03425006 Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer Status TERMINATED Phase PHASE2
NCT03419130 Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer Status WITHDRAWN Phase PHASE2
NCT03414229 A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03410784 Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer Status UNKNOWN Phase PHASE2
NCT03407976 Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies Status TERMINATED Phase PHASE1
NCT03407170 Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161) Status TERMINATED Phase PHASE2
NCT03407144 Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03406858 Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer Status COMPLETED Phase PHASE2
NCT03405792 Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP) Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03402880 ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer Status WITHDRAWN Phase PHASE2
NCT03401853 Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma Status TERMINATED Phase PHASE2